Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LCAR-AIO

Cell therapy (CAR-T) · Kills target cells, directed at CD19 and BCMA (TNFRSF17) · developed by Nanjing Legend Biotech

Phase 1 Most advanced trial (none active)
LEGN Developer
3 Registered trials

What is LCAR-AIO?

LCAR-AIO is a cell therapy of engineered T cells, described as CAR-T cells, that are given after a lymphodepleting conditioning regimen of cyclophosphamide and fludarabine. It is being studied in acute lymphoblastic leukemia, recurrent or refractory B-cell lymphoma, multiple sclerosis, neuromyelitis optica spectrum disease, MOG antibody-associated disorders and myasthenia gravis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen), BCMA (TNFRSF17) (antigen)
Mechanism
Kills target cells, directed at CD19 and BCMA (TNFRSF17)
Therapy area
Oncology
Developer
Nanjing Legend Biotech Co. (LEGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06869278 Phase 1 Multiple Sclerosis (MS) Withdrawn LEGN
NCT05292898 Phase 1 Acute Lymphocytic Leukemia Terminated LEGN
NCT05318963 Phase 1 B-cell Lymphoma Recurrent Terminated LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Lymphocytic LeukemiaB-cell Lymphoma RecurrentB-cell Lymphoma RefractoryMultiple Sclerosis (MS)Myasthenia GravisNeuromyelitis Optica Spectrum Disease (NMOSD)

Other drugs acting on CD19 / TNFRSF17

More from Nanjing Legend Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LEGN page.

Follow LEGN, the company behind LCAR-AIO

See LEGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LEGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.